Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Immuneering (NASDAQ:IMRX) and maintained a price target of $15.
September 13, 2024 | 9:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Immuneering, maintaining a $15 price target, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $15 price target by Needham suggests a positive outlook for Immuneering. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100